Actively Recruiting
Study of ALN-2232 Alone and With Tirzepatide for Safety and Effectiveness in Adults With Obesity
Led by Alnylam Pharmaceuticals · Updated on 2026-08-12
156
Participants Needed
1
Research Sites
44 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating ALN-2232, alone and combined with tirzepatide, in adults with obesity. The study aims to understand the safety, tolerability, effectiveness, and how the body processes these drugs. It includes participants with a body mass index between 30 and 40 kgm and low blood sugar levels, focusing on adults aged 18 to 65 years. Participants will receive either single or multiple doses of ALN-2232 or placebo, with some also receiving weekly doses of tirzepatide. ALN-2232 and placebo are given by injection under the skin. The study is divided into parts Part A involves single doses, while Parts B and C involve multiple doses, including combination with tirzepatide. During the study, participants will have regular visits for up to 12 months to assess safety by tracking adverse events and changes in body weight. Blood and urine samples will be collected to study drug levels and effects on body fat and lean mass. The research team will monitor participants closely throughout to understand the drugs impact on obesity over time.
CONDITIONS
Brief Title
A Study to Evaluate ALN-2232 in Participants With Obesity
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
